Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Beksac, Meral; Seval, Guldane Cengiz; Paydas, Semra; Tuglular, Tulin Firatli; Arslan, Onder; Goker, Hakan; Kaynar, Leylagul; Altuntas, Fevzi; Atalay, Figen; Teke, Havva Uskudar; Bolaman, Ali Zahit; Pehlivan, Mustafa; Sonmez, Mehmet; Demir, Ahmet Muzaffer; Topcuoglu, Pervin; Yilmaz, Mehmet; Kapukcu, Sibel Hacıoglu; Albayrak, Murat; Yurttas, Nurgul Ozgur; Salihoglu, Ayse; Cakar, Merih Kizil; Gurman, Gunhan

DSpace Ana Sayfası
→
Araştırma Çıktıları (WOS-Scopus-TR-Dizin-PubMed)
→
WOS İndeksli Yayınlar Koleksiyonu
→
Öğe Göster

dc.contributor.author	Beksac, Meral
dc.contributor.author	Seval, Guldane Cengiz
dc.contributor.author	Paydas, Semra
dc.contributor.author	Tuglular, Tulin Firatli
dc.contributor.author	Arslan, Onder
dc.contributor.author	Goker, Hakan
dc.contributor.author	Kaynar, Leylagul
dc.contributor.author	Altuntas, Fevzi
dc.contributor.author	Atalay, Figen
dc.contributor.author	Teke, Havva Uskudar
dc.contributor.author	Bolaman, Ali Zahit
dc.contributor.author	Pehlivan, Mustafa
dc.contributor.author	Sonmez, Mehmet
dc.contributor.author	Demir, Ahmet Muzaffer
dc.contributor.author	Topcuoglu, Pervin
dc.contributor.author	Yilmaz, Mehmet
dc.contributor.author	Kapukcu, Sibel Hacıoglu
dc.contributor.author	Albayrak, Murat
dc.contributor.author	Yurttas, Nurgul Ozgur
dc.contributor.author	Salihoglu, Ayse
dc.contributor.author	Cakar, Merih Kizil
dc.contributor.author	Gurman, Gunhan
dc.date.accessioned	2021-08-20T06:47:22Z
dc.date.available	2021-08-20T06:47:22Z
dc.date.issued	2019
dc.identifier.issn	2152-2650
dc.identifier.uri	https://doi.org/ 10.1016/j.clml.2019.09.402	en_US
dc.identifier.uri	http://openaccess.sanko.edu.tr/xmlui/handle/20.500.12527/412
dc.language.iso	English	en_US
dc.publisher	CIG MEDIA GROUP, LP3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931	en_US
dc.rights	info:eu-repo/semantics/closedAccess	en_US
dc.subject	elotuzumab	en_US
dc.subject	immunomodulatory drugs	en_US
dc.subject	Multiple myeloma	en_US
dc.title	Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey	en_US
dc.type	Other	en_US
dc.relation.journal	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	en_US
dc.identifier.issue	10	en_US
dc.identifier.startpage	E242	en_US
dc.identifier.endpage	E243	en_US
dc.identifier.volume	19	en_US
dc.contributor.authorID	0000-0003-4384-2913 : Figen Atalay	en_US
dc.contributor.authorID	0000-0002-2035-9462 : Leylagül Kaynar	en_US
dc.contributor.authorID	0000-0001-9433-2054 : Güldane Cengiz Seval	en_US
dc.contributor.authorID	0000-0003-4642-3693 : Mehmet Sönmez	en_US
dc.contributor.authorID	0000-0002-1263-8947 : Günhan Gürman	en_US
dc.identifier.wos	000491229800399	en_US
dc.identifier.doi	10.1016/j.clml.2019.09.402	en_US
dc.contributor.sankoauthor	Mehmet Yılmaz	en_US